Downregulation of low-density lipoprotein receptor mRNA in lymphatic endothelial cells impairs lymphatic function through changes in intracellular lipids

Laurent Vachon1,2,*, Ali Smaani1,2,*, Nolwenn Tessier1,2,*, Gabriel Jean1,2, Annie Demers2, Andreea Milasan1,2, Nadine Ardo2,5, Stéphanie Jarry1,2, Louis Villeneuve2, Azadeh Alikashani2, Vincent Finherty, Matthieu Ruiz3,4, Mary G. Sorci-Thomas5, Gaétan Mayer2,6, Catherine Martel1,2,6

Abstract

**Rationale:** Impairment in lymphatic transport is associated with the onset and progression of atherosclerosis in animal models. The downregulation of low-density-lipoprotein receptor (LDLR) expression, rather than increased circulating cholesterol level per se, is involved in early atherosclerosis-related lymphatic dysfunction. Enhancing lymphatic function in Ldlr−/− mice with a mutant form of VEGF-C (VEGF-C 152s), a selective VEGFR-3 agonist, successfully delayed atherosclerotic plaque onset when mice were subsequently fed a high-fat diet. However, the specific mechanisms by which LDLR protects against lymphatic function impairment is unknown.

**Methods and results:** We have thus injected wild-type and Pcsk9−/− mice with an adeno-associated virus type 1 expressing a shRNA for silencing Ldlr in vivo. We herein report that lymphatic contractility is reduced upon Ldlr downregulation in wild-type mice only. Our in vitro experiments reveal that a decrease in LDLR expression at the mRNA level reduces the chromosome duplication phase and the protein expression of VEGFR-3, a membrane-bound key lymphatic marker. Furthermore, it also significantly reduced the levels of 18 lipid subclasses, including key constituents of lipid rafts as well as the transcription of several genes involved in cholesterol biosynthesis and cellular and metabolic processes. Exogenous PCSK9 only reduces lymphatic endothelial-LDLR at the protein level and does not affect lymphatic endothelial cell integrity. However, the specific mechanism by which LDLR protects against lymphatic function impairment is unknown.

**Conclusion:** Our results suggest that treatments that specifically palliate the down regulation of LDLR mRNA in lymphatic endothelial cells preserve the integrity of the lymphatic endothelium and sustain lymphatic function, a prerequisite player in atherosclerosis.

**Key words:** Atherosclerosis, Lymphatic System, Lymphatic dysfunction, LDLR, PCSK9

Introduction

Four decades ago, Lemole suggested that intimal arterial thickness was associated with lymphatic vessel blockage [1]. He proposed that enhanced stagnation of the interstitial fluid in the arterial wall could be due to lymphostasis [1, 2]. Since then, in addition to the well-described classical roles of the lymphatic network [3, 4], studies analyzing the morphology of lymphatic vessels in the artery wall shed light on their associations with atherosclerosis [5-8]. Subsequently, functional studies have then proven that the absence of functional adventitial lymphatics is associated to an exacerbated
atherosclerotic plaque accumulation in mice [9, 10]. It is now well accepted that an efficient lymphatic drainage is crucial for atherosclerosis regression [9, 11, 12]. The first studies on the topic were suggesting that hypercholesterolemia was at the corner stone between cardiovascular disease and lymphatic function [10, 13, 14]. Recently, the role of the lymphatics has been refined throughout the development of the atherosclerosis process, placing front stage the potential role of an early lymphatic dysfunction before the onset of the disease [15, 16]. Our team has reported that lymphatic function impairment occurs even before the onset of atherosclerosis in Ldlr+/−; hapoB100+/+ mice [16]. The absence of low-density lipoprotein receptor (LDLR), but not the increase in circulating cholesterol levels, is potentially instigative of this early atherosclerosis-related collecting lymphatic vessel dysfunction [16]. We have subsequently found that enhancing collecting lymphatic vessels with a mutant form of the vascular endothelial growth factor-C (namely VEGF-C 152S) early on in the atherosclerotic process protects from subsequent excessive plaque formation in Ldlr+/− mice [15]. On the other hand, our team has also demonstrated for the first time that a systemic knockout in proprotein convertase subtilisin kexin type 9 (PCSK9) improves lymphatic transport in conjunction with increasing LDLR expression in lymphatic endothelial cells (LEC) in six-month-old mice compared to wild-type mice [16]. As PCSK9 deletion did not affect lymphangiogenesis per se, these results suggest that collecting lymphatic vessels are primarily involved.

PCSK9 is capable of binding LDLR, leading to its internalization and degradation in lysosomes [17]. The degradation of this complex is regulated by PCSK9 and LDLR levels, but also by a variety of other proteins [18-20]. PCSK9 also has pleiotropic effects including in cardiovascular metabolism. It has been reported to promote the internalization and degradation of other receptors and members of the LDLR superfamily [21-25]. Albeit PCSK9 has been extensively studied in plasma [26, 27], it is only recently that its accumulation in systemic lymph has been reported [16]. Whether PCSK9 is produced by LEC or if it affects lymphatic function via LDLR binding or through other pleiotropic mechanisms is not known yet. Using an in vivo model of induced endothelial deletion of Ldlr, we herein report that lymphatic contractility is reduced upon Ldlr downregulation in wild-type male mice, but not in Pcsk9+/− mice. LDLR expression had to be decreased at the mRNA level to observe a reduction in the chromosome duplication phase and in the protein expression of VEGFR-3, a membrane-bound key lymphatic marker. Exogenous PCSK9 only reduces LEC-LDLR at the protein level and does not affect lymphatic endothelial cell integrity. This put forward that PCSK9 may act upon lymphatic muscle cells to mediate its effect on lymphatic contraction capacity in vivo. Lipidomic and transcriptomic analysis further revealed that the levels of crucial constituents of lipid rafts and the transcription of several genes involved in cholesterol biosynthesis and cellular and metabolic processes were also reduced upon LDLR mRNA downregulation in LEC. Globally, our study suggests that treatments that specifically palliate the down regulation of LDLR mRNA in lymphatic endothelial cells might preserve the integrity of the lymphatic endothelium and sustain lymphatic function, a prerequisite player in atherosclerosis.

Materials and methods

Adeno-associated virus (AAV) vector constructs

Single-stranded cDNA (sscDNA) containing different short hairpin RNA (shRNA) flanked by HindIII and BamHI sites and two linkers were purchased from IDT and amplified by PCR using forward and reverse linker primers (Table 1). Double-stranded amplicons were digested with the two restriction sites, gel-purified and ligated in pU6-ITR, followed by transformation in Stbl3 bacteria. All used clones were confirmed by sequencing and purified by Maxiprep (Qiagen, Catalog No. D4202).

AAV type 1 (AAV1) production and purification

Human embryonic kidney 293T (HEK 293T) cells were seeded in sixteen 100 mm plates in DMEM without sodium pyruvate (Wisent cat. 319-015) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Wisent cat. 080-150). Once they had reached 70-80% confluence, cells were transfected with 8.6 µg/plate of the packaging plasmid pXYZ and 2.9 µg/plate of the specific pU6-ITR-sh plasmid (pU6-ITR-AAV1-sh-mLdlr or pU6-ITR-AAV1-sh-scramble) using the polyethylenimine method (46 µL/plate, PEI; Polysciences, cat. 23966). Cells were harvested 72 h post-transfection with a cell scraper, pelleted, resuspended in Tris lysis buffer (150 mM NaCl, 50 mM Tris pH 8.5) and subjected to three freeze/thaw cycles. Cell lysates were treated with 1 mM of MgCl2 and 250 units of benzonase (Santa Cruz cat. sc-202391) for 45 min at 37 °C and then centrifuged 20 min at 6000 g to remove cell debris. The lysate was purified by iodixanol gradient. Briefly, 60% iodixanol (OptiPrep; Sigma D1556) was diluted to

https://www.thno.org
40% and 25% in 5X PBS-MK (5X PBS, 5 mM MgCl2, 12.5 mM KCl). Then, 2.5 µL of 0.5% phenol red (Bioshop PHE600.5/5g) was added to the 25 and 60% iodixanol phase. One milliliter of 60, 40, and 25% iodixanol solutions was successively added in a 5-mL Beckman ultracentrifuge tube (catalog No# 326819), and 1.5 to 2 mL of the processed crude lysate was gently overlaid onto the gradients and centrifuged in a 5Ti rotor for 3 h at 33000 rpm at 4 °C. After centrifugation, the tubes were punctured at the 60% and 40% interphase (bottom and middle layers) using a 18-gauge needle, to collect ~1 mL/tube of the fraction containing the virus. A pool of collected iodixanol containing virus was cleaned with PBS-0.001% Tween and concentrated with an Amicon Ultra-15 centrifugal filter unit (MWCO 100kDa; Merck Millipore cat. UFC90024). The virus was then titrated by quantitative PCR using AAV ITR primers (Table 1) and a standard curve using the corresponding pU6-ITR-sh plasmid in serial dilutions. Finally, viral batches were aliquoted and stored at -80 °C.

Table 1. List of sequences for AAV1-shRNA, siRNA and primers used throughout the study. AAV, Adeno-associated virus

| AAV1-shRNA | 5'-CGAGGGCAGCTAATGCTAG-3' |
| shLdlr | 5'-TATTAGGGAGATGCGGACT-3' |
| siRNA | 5'-CTGGGTGACTGCAATCTCA-3' |

**Experimental mouse model**

C57BL/6 wild-type and Pcsk9 knockout (Pcsk9−/−) mice were obtained from the Jackson Laboratory. The Pcsk9−/− mice were backcrossed on a C57BL/6 background for at least 10 generations at our facility. Animals were housed in a pathogen-free environment under 12 h light-dark cycles with free access to water and to standard chow diet. Ten-12-week-old male and female mice were injected into the peritoneal cavity with 1x1011 viral genomes per 150 µL of an adeno-associated virus type 1 (AAV1) expressing mouse LDL-receptor shRNA (shLdlr) or a scramble shRNA (shSCR) (Table 1). Mice were euthanized with isoflurane (2%) and CO2 two weeks later and perfused with PBS. The liver, aorta and popliteal lymph nodes (LN) were harvested and processed for the assessment of LDLR protein (flow cytometry and western blot) or mRNA (qPCR) expression. All experiments were performed in accordance with the Canadian Council on Animal Care guidelines and approved by the Montreal Heart Institute Animal Care Committee (protocol #2019-14-02).

**Measurement of lymphatic function in vivo**

Migration of dendritic cells to LN was evaluated following a contact sensitization assay [16]. Briefly, the animals were sacrificed 18 h after an epicutaneous application of a solution containing fluorescein isothiocyanate (FITC) (Sigma Aldrich cat. #F7250-250MG), dibutyl phthalate and acetone (Sigma Aldrich), and corresponding skin-draining LNs were collected and enzymatically digested in collagenase D (Cedarlane cat. #1108882001) for 25 min at 37 °C. Cells were passed through a 70 µm strainer, washed, counted and stained for analysis by flow cytometry (BD FACSCelesta™). The following fluorescence-conjugated antibodies were used: anti-mouse CD11b PerCP-Cy5.5 (BioLegend cat. #101228), anti-mouse CD11c BV786 (BD Biosciences cat. #563735) and anti-mouse MHCII PE (Tonbo Biosciences cat. #35-5321-U100). The percentage of FITC-positive dendritic cells that migrated to the corresponding draining lymph nodes was analyzed with FlowJo™ software (Tree Star Inc.).

**In vivo measurement of lymphatic vessel contraction**

Mice were anesthetized with isoflurane (2%) and oxygen (2%), placed in abdominal decubitus on a heat pad at 40 °C and the contraction capacity of the popliteal lymphatic measured as previously described [15, 28], with minor modifications. Briefly, 10 µL of Alexa-Fluor 647-conjugated ovalbumin (2 mg/mL, Thermofisher Scientific cat. #O34784) was injected in the dermis of the footpad followed by three manual contractions of the leg and a smooth massage of the injection site. After 5-10 min, the lymphatic contractions were recorded for 10 min with the Axiozoom V.16 microscope (Zeiss). A total of 326 pictures per imaging session were taken with an exposure time of 1 s. Images were stabilized using the Template Matching ImageJ™ plugin and analyzed with the LymphPulse 3.0 Matlab™ based software (Figure S1). Five regions of interest (ROI) were manually sketched on each lymphatic vessel and the
background intensity was subtracted. The projected curves displayed peaks and valleys with a detection threshold placed at 40 arbitrary units (AU) by the user. The contraction frequency was then computed from each curve with a Matlab algorithm following the formula \((Np+Nv)/(2*dt)\), where \(Np\) et \(Nv\) are the number of peaks and number of valleys, respectively, and \(dt\) is the analysis time. The contraction amplitude was calculated as the mean fluorescence intensity (MFI) change within each contraction out of the maximum fluorescence intensity reached from each ROI and expressed in percentage.

**Cell culture**

Primary human dermal lymphatic microvascular endothelial cells from adult donors (HMVEC-dLyAd), called human lymphatic endothelial cells (LEC) throughout the manuscript, were cultured according to the manufacturer’s protocol (Lonza cat. #CC-2810) in EBM-2 medium containing the EGM-2 MV SingleQuots (PromoCell) in 5% CO₂ atmosphere at 37 °C. Cells were seeded in 6-well cell culture plates, incubated in FBS-free media for 1 h and treated with either human recombinant PCSK9 or vehicle control in FBS-free media (6.5 μg/mL, ProSci cat. #96-577) for 16 h or transfected with human LDLR siRNA (25 nM, Qiagen Hs_ LDLR_2 cat. #SI00011172 or Hs_LDLR_3 cat. #SI00011179) or non-targeting siRNA (Qiagen cat. #1027280) for 48 h in EGM-2 MV using TransIT-X2® Dynamic Delivery System (MirusBio cat. #MIR6003). Human hepatoma cell lines HepG2 and Huh7 cells and HEK 293T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Wisent cat. 319-005-CL) containing 10% FBS (Wisent cat. 080-350) in a 5% CO₂ atmosphere at 37 °C. Cells were used at 70-90% confluency for all experiments. To exclude any siRNA off-target effect, two sequences were used (Table 1), herein called siLDLR2 and siLDLR3.

**Detection of lymphatic markers by flow cytometry**

Human LEC (or human hepatoma Huh7) cells were harvested from the cell culture plates and centrifuged at 430 g for 5 min. All sample cells were suspended in PBS supplemented with 0.1% (vol/vol) bovine serum albumin (BSA) and 0.1% sodium azide. The following fluorescence-conjugated antibodies were used in this study: anti-human LDLR (clone ID 301, SinoBiological cat. #10231-R301-A), anti-human VEGFR-3 (clone ID 9D9F9, BioLegend cat. #356204), anti-human LYVE-1 (Invitrogen cat. #PA5-22782) and anti-human podoplanin (clone ID NC-08, BioLegend cat. #337012). Flow cytometry was performed using the BD FACSCelesta™ and data were analyzed using FlowJo™ software (Tree Star Inc.). Otherwise, results are expressed as mean fluorescence intensity (MFI) and each treatment was normalized to its respective control.

**Assessment of cell cycle distribution**

Human LEC were fixed in cold 70% ethanol, washed and stained with a propidium iodide (PI) solution (Biotium cat. #40017), which is fluorogenic and binds to nucleic acids in a stoichiometric manner to allow the assessment of the proportion of cells in each phase of the cell cycle (pre-replicative (G0/G1), replicative (S) and post-replicative and mitotic cells (G2/M)) [29]. Flow cytometry was performed using the BD FACSCelesta™ and data were analyzed using FlowJo™ software (Tree Star Inc.).

**Measurement of LDL internalization**

LDL internalization by human LEC was determined by flow cytometry (BD FACSCelesta™) following a 4 h incubation with 10 μg/mL of Dil-LDL (Alfa Aesar™ cat. #1330AMH). Unless indicated otherwise, results are expressed as mean fluorescence intensity (MFI) and each treatment was normalized to its respective control.

**Quantification of extracellular vesicle production in cell culture media**

Following the 48 h treatment with siLDLR (or siControl), the cell culture supernatant was collected and the concentration of human LEC-derived extracellular vesicles (EV) determined by flow cytometry (BD FACSCelesta™). For EV analysis, the 450/40 bandpass filter (BV421, violet laser) was manually swapped after cytometer setting and tracking (CS&T) calibration with a 1 mm-thick magnetron sputtered 405/10 bandpass filter (Chroma Technology, Bellows Falls, VT, USA), which is referred as V-SSC in this manuscript. Plots and histograms are showing all parameters in height (indicated as –H), as recommended for EV detection [30]. Events were acquired at a flow rate of 12 μL/min, which is the lowest flow rate on the FACSCelesta. The flow rate during acquisition was kept to the minimum to avoid swarming effects and coincident detection [31]. For a more precise calibration for assessment of biological vesicle size (refractive index in the range 1.36 to 1.42), the flow cytometer was calibrated for EV detection using the ApogeeMix (#1493, Apogee Flow Systems, Hemel Hempstead, UK), which consists of a mixture of non-fluorescent silica beads (180, 240, 300, 590, 880, and 1300 nm) and FITC-fluorescent latex beads (110 and 500 nm) (Figure S2). The EV gate was set to contain events ranging from -100 to -1000 nm using the size of the non-fluorescent silica beads in the ApogeeMix, whose refractive index is close to that of
cellular membranes [32]. The threshold for the forward scatter (FSC) detector was set at the lowest possible value (200 V) in FACS Diva software (BD Biosciences). EV were stained with CFSE (esterase activity, eBioscience cat. #65-0850-84) [33] and antibodies against CD31 (clone ID WM59, BD Biosciences cat. #563653) and VEGFR-3 (clone ID 9D9F9, BioLegend cat. #356204). The background in the EV gate was determined by running samples containing all reagents and antibodies except EV-containing culture media and was subtracted from the values obtained for samples with EV-containing culture media. To confirm the cellular origin of the vesicles detected, 0.1% Triton X-100 (0.05% final concentration) was added to the samples for 30 min, and the decrease in EV count denoted. The absolute concentration of EV/mL was calculated using count beads (#1426, Apogee Flow System) and the formula: 
\[
\text{(# of events in EV gate/ # of events in count beads gate)} \times \text{(total number of beads in sample/sample volume)} \times \text{dilution factor}
\]
Data were analyzed using FlowJo™ software (Tree Star Inc.).

**Immunofluorescence**

LDLR expression was also determined by immunofluorescence on human LEC seeded in glassbottom culture dishes chamber (MatTek). Live cells were stained for 30 min at 37 ℃ with anti-human LDLR Alexa Fluor 647 Conjugate (Bioss cat. #bs-0705R), Cholera Toxin Subunit B Alexa Fluor 555 Conjugate (Invitrogen cat. #C-34776) and nuclei marker DAPI (4',6-diamidino-2-phenylindole, BioShop cat. #DAP444.5). Live images were acquired at 37 ℃, 5% CO2 with a LSM 710 Confocal Microscope (Zeiss) equipped with a 63/1.4 oil DIC objective. Z-stacks were deconvolved with Huygens Professional (Scientific Volume Imaging, SVI, Netherlands) using a theoretical spread function (PSF). Three-dimensional rendering and quantitative colocalization (whole volume) analysis of LDLR and cholera toxin was estimated (Colocalization Analyzer, SVI) using Pearson’s correlation coefficient, for which an absolute value of one indicates a perfect linear relationship, whereas a correlation close to 0 indicates no linear relationship between the variables.

**Immunoblotting**

Proteins were extracted from either human LEC, human HEK 293T, human liver cell lines (HepG2 or Huh7) or mouse tissues (liver or aorta) using ice-cold radioimmunoprecipitation (RIPA) assay buffer and the protein concentration of the supernatants were established using MicroBCA™ Protein Assay Kit (ThermoFisher). Protein samples were diluted in 4X Laemmli buffer, heated at 95 ℃ for 5 min, separated by electrophoresis on a 10% SDS-PAGE and then transferred on a polyvinylidene fluoride (PVDF) membrane for 90 min at 4 ℃. The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (TBST, 0.1% Tween 20) for 1 h at room temperature. PVDF membrane containing protein isolated from the various cell lines were then incubated overnight at 4 ℃ with anti-human PCSK9 (Abcam cat. #AB95478), anti-human LDLR (R&D Systems cat. #AF2148-SP), or anti-human beta-actin (Abcam, AB8227). For mouse tissues, anti-mouse LDLR (RD Systems, cat. #AF2255) and anti-mouse GAPDH (Invitrogen cat. #AM4300) were used. The membranes were washed with TBST and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Abcam, AB6721 or AB6741) for 90 min at room temperature. A Clarity™ Western ECL Blotting Substrates Kit (Thermofisher cat. #PI32209) was used for detection.

**ELISA**

PCSK9 was measured according to the manufacturer’s instructions (Human Proprotein Convertase 9/PCSK9 Quantikine ELISA Kit) (R&D Systems cat. #DPC900) in human LEC, HuH7 and HEK 293T supernatants that were concentrated using the Amicon® Ultra-2 centrifugal filter device (Milipore).

**Messenger RNA analysis by RT-qPCR**

Treated cells were harvested, suspended in RiboZol™ RNA Extraction Reagent (VWR cat. #CA97064-950) and stored at -80 ℃ for at least 24 h. The RNA was extracted using the PureLink RNA Mini Kit extraction kit (Invitrogen cat. #12183018A) according to the manufacturer’s protocol and quantified on a NanoDrop™ 1000 Spectrophotometer (ThermoFisher). Reverse transcription of RNA was performed using the iScript kit cDNA synthesis kit (Thermofisher cat. #4368814). Quantitative PCR was performed on the QuantStudio™ 3 (ThermoFisher Scientific) using 10 ng/well of complementary DNA (cDNA) mixed with iTaq™ Universal SYBR Green Supermix (Biorad cat. #1725121). The primers used are displayed in Table 1. The amplification cycles were performed at 94 ℃ for 10 s and at 60 ℃ for 45 s. The relative expression was evaluated using the comparative method (2-ΔΔCT) and normalized to the control gene.

**Transcriptomic analysis**

Samples were submitted for Illumina next-generation sequencing to the IRIC Genomics Platform. Adaptor sequences and low-quality bases in the resulting FASTQ files were trimmed using Trimmomatic version 0.35 [34] and genome
alignments were conducted using STAR version 2.7.1a [35]. The sequences were aligned to the human genome version GRCh38, with gene annotations from Gencode version 37 based on Ensembl 103. As part of quality control, the sequences were aligned to several different genomes to verify that there was no sample contamination. Gene expressions were obtained both as raw readcount directly from STAR as well as computed using RSEM [36] in order to obtain gene and transcript level expression in reads per transcripts per million (TPM) for these stranded RNA libraries. DESeq2 version 1.22.2 [37] was then used to normalize gene readcounts and compute differential expression between the various experimental conditions. Sample clustering based on normalized log read counts produces a hierarchy of samples.

**Non-targeted lipidomic by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS)**

The LC-QTOF-MS was performed by the Montreal Heart Institute Metabolomics core facility as previously described [38]. Cells were seeded in 60 mm glass petri dishes (Pyrex™ cat. #C316060) to avoid polymer (polyethylene glycol, PEG) contamination, and treated as described above. Cells were then harvested, washed, and suspended in 1 mL of serum-free medium. Lipids were extracted following the addition of internal standards (monocacylglycerosphosphocholine (LPC) 13:0, diacylglycerophosphocholine (PC) 14:0/14:0 and 19:0/19:0, phosphatidylserine (PS) 12:0/12:0, diacylglycerophosphoethanolamine (PE) 17:0/17:0, and diacylglycerophosphoglycerol (PG) 15:0/15:0)) and injected into a high performance liquid chromatograph (1290 Infinity HPLC) coupled to quadrupole time-of-flight mass spectrometry (Agilent Technologies Inc.) equipped with a dual electrospray ionization source and analyzed in positive and negative mode. The lipid elution was carried out on a Zorbax Eclipse plus column (C18, 2.1 mm × 100 mm, 1.8 μm, Agilent Technologies Inc.) for 83 min at a constant temperature of 40 °C in a gradient of solvent A (0.2% Methanoic acid and 10 mM ammonium formate in water) and B (0.2% methanoic acid and 5 mM ammonium formate in methanol/acetonitrile/methyl tert-butyl ether [MTBE], 55:35:10 [v/v/v]). Mass spectrometry data analysis was performed with the Mass Hunter Qualitative Analysis software (B.07 version) and discriminant lipids were identified by Tandem Mass Spectrometry (MS/MS). Statistical analyzes were carried out by unpaired Student’s t-test followed by Benjamini-Hochberg correction with the program Mass Professional Pro version 12.6.1 (Agilent Technologies Inc.).

**Cholesterol measurement**

Blood was collected on 100 mM ethylenediamine tetraacetic acid (EDTA) by cardiac puncture and plasma was obtained from wt and Pcsk9−/− mice following centrifugation at 2400 g for 10 min and were stored at −80 °C. Mouse lipoproteins were separated from plasma by size exclusion chromatography [fast protein LC (FPLC)] using a Superose 6 column on a FPLC system with a Model 500 pump from Waters (Milford, MA). In short, a 100 μL aliquot of mouse plasma pooled equally from four (4) different mice was injected into a 1.0-mL sample loop and separated with PBS at a flow rate of 0.5 mL/min. Sixty-five fractions of 0.3 mL each were collected with the lipoproteins being contained within. Batch analysis was performed to measure circulating total cholesterol (Fujifilm Medical Systems U.S.A., Inc. cat. #999-02601) in plasma and plasma lipoprotein fractions according to the manufacturer’s protocol. For the in vitro experiment, total cholesterol measurement was performed according to the manufacturer’s protocol (Total Cholesterol E, Fujifilm Medical Systems U.S.A., Inc. cat. #999-02601) in cell culture media as well as in human LEC-derived EV (elicited with Triton X-100) following the 48 h treatment with LDLR siRNA or non-targeting siRNA.

**Statistics**

Data are expressed as mean ± standard error of the mean (SEM). Statistical significance was evaluated by unpaired t test or, for multiple comparisons, one-way ANOVA using appropriate corrections when data was not normally distributed, or for unequal variances. Each in vitro experiment was performed in triplicate. All calculations were done with GraphPad Prism v8 software (GraphPad Software, La Jolla, CA, USA), and p-values <0.05 were considered statistically significant.

**Results & Discussion**

Acute exposure of collecting lymphatic vessels to LDL in mice increases contraction frequency and lymph flow [39]. Therefore, LDL binding to LDLR could appear as an attractive target in preserving lymphatic function. However, lymph is rich in high-density lipoprotein (HDL) and chylomicron, but rather comparatively poor in LDL [40], which rises the concern on the physiological relevance of this previous finding. Furthermore, LDLR deficiency has been associated to an early lymphatic dysfunction in pre-atherosclerotic mice before major changes in circulating lipid levels [16]. The injection of VEGF-C 152S before the administration of a pro-atherogenic regimen improves lymphatic contraction capacity in Ldlr−/− mice and protects them from excessive plaque
formation [15]. Therefore, we hypothesize that LDL binding to LDLR on lymphatic endothelial cells levels would only have a minor role, if any, in maintaining lymphatic contraction capacity in the initial steps of atherosclerosis. We thus sought to determine whether and how lymphatic endothelial-LDLR might modulate lymphatic function.

**Decreasing Ldlr expression in lymphatic endothelial cells does not alter plasma lipoprotein distribution nor dendritic cell transport through lymphatics in 3-month-old mice**

_Pcsk9−/−_ mice display improved dendritic cell migration through the lymphatics in 6-month-old mice, but not in 3-month-old mice, compared to age-matched wild-type animals [16]. As lymph and plasma PCSK9 levels are increased in LDLR-deficient mice compared to control mice [16], we have first tested whether PCSK9 is essential in disrupting lymphatic transport in the absence of LDLR in vivo. We have injected 3-month-old _Pcsk9−/−_ or wild-type mice with an adeno-associated virus type 1 (AAV1) expressing mouse LDL-receptor shRNA (shLdlr) or a scramble shRNA (shSCR) sequence (Table 1). The AAV1 containing the shLdlr efficiently decreased LDLR expression in endothelial cells as revealed by flow cytometry (Figure 1A, see Figure S3 for gating strategies) and immunoblotting (Figure 1C) whereas it had no effect in the liver (Figure 1D) or lymph-node CD45+ cells (Figure 1B). We have already published that _Pcsk9−/−_ mice have more membrane LDLR-LEC than their wild-type controls, as represented by immunofluorescence [16]. Immunoblotting show that total LDLR protein levels in the liver were higher in _Pcsk9−/−_ mice compared to wild-type animals [41] (Figure 1D). Decreasing LDLR levels on endothelial cells had no effect on the plasma lipoprotein distribution in wild-type or _Pcsk9−/−_ mice (Figures 1E and 1F, respectively). This excludes that circulating cholesterol might act as a major contributor of the modulation of lymphatic function when LDLR is downregulated. Furthermore, neither _Pcsk9−/−_ nor wild-type mice had significant changes in dendritic cell transport within lymphatic vessels (Figures S4A-B, see Figure S4C for gating strategies) [16] following shLdlr or shSCR injection. This implies that there is no apparent impairment in lymphatic transport yet in these 12-week-old mice.

**PCSK9 is needed to reduce lymphatic contraction capacity in endothelial-specific LDLR knockdown mice**

Mice deficient in _Ldlr_ display an impaired lymphatic contractility at 12-week-old, prior to a disrupted lymphatic transport and atherosclerotic plaque formation [15, 16, 42]. Consequently, we thus next investigated whether a failure in the contraction capacity could also be observed in mice treated with shLdlr. Using intravital imaging, the capacity of the popliteal collecting lymphatic vessel to contract was evaluated following the injection of fluorescent ovalbumin (Figure S1). Knocking-down LDLR expression in lymphatic endothelial cells significantly decreased the number of contractions per minute observed in wild-type male mice (Figure 1G). It had no effect in wild-type females (Figure 1G), despite its efficiency to decrease total endothelial-LDLR expression (Figures 1A and C). Contractions also remained unchanged in _Pcsk9−/−_ mice, of both sexes (Figure 1H). Thus, PCSK9 seems to be needed to reduce lymphatic contraction capacity in endothelial-specific LDLR knockdown mice, nonetheless in a sex-specific manner. It could partially be explained by the more modest decrease in membrane-LDLR observed following shLdlr injections in these mice (Figure 1A, shift of the histogram toward the left), concurring with studies affirming that the absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR [41]. _Ldlr_ mRNA levels have also been described as less sensitive to estrogen hormone variations in mice lacking PCSK9 [41], which might be a cause of the differences we herein observe between wild-type and _Pcsk9−/−_ male and female mice. Circulating PCSK9 interacts with reactive oxygen species (ROS) and promotes vascular aging and atherosclerosis progression [43]. ROS production is closely linked to nitric oxide (NO) generation and elevated levels of ROS lead to low NO bioavailability, as observed in mice that are systemically lacking LDLR [44]. Like in blood vessels, NO is a fine regulator of lymphatic function, mainly through the regulation of collecting lymphatic vessel contractions [45]. ROS negatively influences lymphatic contractile function [46], and under inflammatory conditions, lymphatic contraction frequency is reduced due to the increase secretion of NO from the inducible nitric oxide synthase (iNOS) [47]. One of the major driving forces of lymphatic pumping is the surrounding layer of muscle cells whose activity largely depends on intracellular Ca2+ levels [48]. Ca2+ levels are modulated by NO levels produced by the endothelial NOS (eNOS) under physiological conditions. Estrogen receptor alpha (ERα) signaling has recently been suggested to protect from lymphatic dysfunction [49]. Besides, the estradiol (E2)/ERα specific binding regulates the expression of several genes, including _Ldlr_ [50] and endothelial NOS (enos) [51]. The reduced estrogen production in the female mice used in our
A study compared to age-matched male mice [52] might limit nitric oxide (NO)-dependent contractile forces in the lymphatic endothelium.

**Figure 1. Lymphatic function assessment in mice following a specific knockdown of LDLR in murine endothelial cells.** Two weeks after the intraperitoneal injection of an adeno-associated virus type 1 (AAV1) containing a shRNA targeting LDLR, skin draining lymph nodes were harvested, digested and analyzed by flow cytometry to assess lymphatic endothelial cell (LEC)-specific knockdown of LDLR expression in mice. Membrane-bound LDLR expression was measured on (A) CD45-CD31+/Podoplanin+ and (B) CD45+ cells. Fluorescence minus one (FMO) control was used for LDLR expression, as depicted by the dotted line in the first histogram. White histogram, shSCR and dark histogram, shLdlr. LDLR expression was also determined by immunoblotting in (C) aorta isolated from female mice and (D) in liver from wild-type and Pcsk9−/− male (full dot) and female (empty dot) mice. ShSCR in black and ShLdlr in grey. Total plasma cholesterol was measured following FPLC in each lipoprotein subfraction in (E) wild-type and (F) Pcsk9−/− female (dotted lines) and male (solid lines) mice treated with shSCR (black lines) and shLdlr (grey lines). Lymphatic contraction capacity was assessed by fluorescent in vivo imaging in (G) wild-type and (H) Pcsk9−/− mice. Black histogram, ShSCR and grey histogram, ShLdlr. n=3-9. Statistics **p < 0.01.
Human lymphatic endothelial cells do not express nor secrete PCSK9

We then sought to investigate in further details how PCSK9 and LDLR can affect lymphatic function at the cellular level. As PCSK9 enhances pro-inflammatory reactions in the vascular wall [53-56], we hypothesized that PCSK9 might trigger similar effects on lymphatic endothelial cells. Our laboratory has demonstrated that PCSK9 circulates in mouse lymph and that lymphatic function is improved in 6-month-old $\text{Pcsk9}^{-/-}$ mice [16]. However, the source of PCSK9 in lymph remains unknown. We herein show that lymphatic endothelial cells do not express (Figure 2A) nor secrete (Figure 2B) PCSK9. Therefore, LEC, like other cell types that do not produce PCSK9 [22], are probably elicited by circulating PCSK9 produced mainly by the liver, and retrieved in lymph [16].

LDLR is localized in lipid rafts in human lymphatic endothelial cells

PCSK9 is typically recognized for its role in the regulation of cholesterol metabolism; it binds hepatic LDLR and induces its degradation in lysosomes leading lower cell surface LDLR and to an increase in plasma LDL-cholesterol [57]. In the past decade, PCSK9 has been studied for its role in atherosclerosis through pleiotropic effects on diverse cell types [58-60]. It has been reported that circulating PCSK9 contributes directly to the progression of atherosclerosis by enhancing blood endothelial cells dysfunction independent of its effect on the LDLR [61]. We herein sought to define whether PCSK9 can control LDLR expression or if it rather acts through an LDLR-independent mechanism. We have previously demonstrated that LDLR is expressed on mice LEC, but not on lymphatic muscle cells [16]. Our second step in vivo was consequently to highlight whether and how LDLR is expressed on human LEC. The expression of LDLR was first confirmed by immunoblotting in whole cell lysates of human LEC, HepG2 and HEK 293T (Figure 2C). Flow cytometry allowed for the detection of membrane LDLR on human LEC (Figure 2D). Immunofluorescence images revealed that LDLR is mostly likely located in the lipid rafts (Figure 2E), as it is positively correlating with the presence of GM1 gangliosides labeled by cholera toxin subunit B (Pearson coefficient, 0.804; Figure 2F) within the cells. Interestingly, on other cell
types, LDL binds to the LDLR in clathrin-coated pits, rather than LDLR-associated with lipid rafts [62]. Our finding highlights the unique regulation of LDLR in LEC and suggests that the binding of ligands other than LDL modulates its expression.

**LDLR expression remains unchanged upon LDL internalization by human lymphatic endothelial cells**

To further study the physiological role of LDLR-LEC, we incubated human LEC with fetal bovine serum (FBS)-free media for 24 h and cell surface expression of LDLR was measured by flow cytometry. Decreasing surrounding lipid content increased LDLR levels on the cell membrane (Figure 3A). However, when incubating human LEC with dil-LDL, LEC could efficiently internalize LDL (Figures 3B-C) despite no changes in membrane LDLR, as determined by flow cytometry (Figure 3D). Therefore, LDLR modulation on LEC could have completely

![Figure 3. LDLR regulation in human LEC. (A) Cell surface expression of LDLR was measured by flow cytometry after incubating human LEC with (ctl) or without FBS-containing media for 24 h. (B) Human LEC were incubated with Dil-LDL for 4 h and LDL uptake was measured by flow cytometry (dotted line, no LDL; grey line, Dil-LDL). (C) The percentage of LDL internalization compared to control as well as (D) cell surface expression of LDLR was then quantified by flow cytometry. Human LEC were incubated with exogenous human recombinant PCSK9 (6.5 µg/mL) for 16 h and LDLR protein expression was detected and quantified by (E) immunoblotting, (F) flow cytometry and (G) LDLR messenger RNA by qPCR. (H) Immunofluorescence confirmed LDLR expression in human LEC. Representative scatterplot of red and green pixel intensities of cholera toxin subunit B (red) and anti-LDLR (green) in lymphatic endothelial cells and a reconstruction of colocalized voxels (scale bar, 20 µM). (I) Protein expression of VEGFR-3 was measured in human LEC by flow cytometry following 16 h incubation with 6.5 µg/mL human recombinant PCSK9. n=3-9. Statistics: *p < 0.05, ***p < 0.001, ****p < 0.0001.](https://www.thno.org)
different physiological functions than on any other cell type and affect lymphatic function in a mechanism that is independent of its LDL binding properties. Apolipoprotein (apo) B and apoE-containing particles other than LDL might bind to LDLR, which could mediate their internalization in LEC. This mechanism remains to be tested.

**Exogenous PCSK9 decreases LDLR protein but not Ldlr mRNA expression in human lymphatic endothelial cells**

As hepatic and extra-hepatic cells such as fibroblasts are also known to overexpress LDLR when incubated with serum-depleted medium [63, 64], we then investigated whether LDLR levels on LEC would also be modifiable through the action of PCSK9. We incubated human LEC for 16 h with recombinant PCSK9 (6.5 μg/mL) and observed a decrease in total LDLR protein by immunoblotting (Figure 3E) and a 90% decrease of the membrane-bound LDLR protein by flow cytometry (Figure 3F). Yet, no reduction in LDLR mRNA was denoted (Figure 3G). Further, exogenous PCSK9 did not affect the Pearson coefficient assessing the colocalization between LDLR and cholera toxin subunit B (average of 0.694 with exogenous PCSK9 vs. 0.804 for control; Figure 3H). Our findings report that PCSK9 treatment modulates LDLR expression at the protein level but not at the mRNA level.

**Exogenous PCSK9 does not modulate the expression of lymphatic markers nor the endothelial cell cycle**

Signaling by vascular endothelial growth factors (VEGFs) through VEGF receptors (VEGFRs) plays important roles in vascular development [65]. VEGFs bind to the three known VEGFRs, VEGFR-1, VEGFR-2 or VEGFR-3, which are expressed by blood vessel endothelial cells in case of VEGFR-1 and -2, and LEC in case of VEGFR-2 and -3. Specific activation of VEGFR-3 by VEGF-C 156S, a selective VEGFR-3 agonist, stimulates lymphatic pumping by a VEGFR-3-dependent mechanism [66] and downregulates many genes involved in immune regulation and inflammation [67], suggesting that VEGFR-3 stimulation has direct anti-inflammatory effects. Furthermore, lymphatic transport can be restored in Ldlr-/- mice by systemic injections of an analogue of VEGF-C 156S, namely VEGF-C 152S. We have herein demonstrated in vivo that PCSK9 might be a key contributor of lymphatic contraction and function impairment, but the underlying mechanisms remain to be investigated. PCSK9 inhibitors have been shown to increase VEGFR-2+ endothelial progenitor cells [68] and increase VEGF release into supernatants of blood endothelial cells in vitro [69]. We herein wanted to assess whether PCSK9 treatment would decrease VEGFR-3 expression on human LEC. Albeit it decreased LDLR protein expression (Figures 3E-F) without however altering the transcription of the protein (Figure 3G) [70], exogenous PCSK9 had no effect on VEGF-3 protein expression (Figure 3I) or other lymphatic markers such as LYVE-1 (Figure S5A) or podoplanin (Figure S5B). RNA sequencing first confirmed that exogenous PCSK9 had little to no effect on gene expression (data not shown). The only gene that appeared upregulated upon PCSK9 treatment is ATAD3C (data not shown). ATPase family AAA domain-containing protein 3 (ATAD3C) is a mitochondrial membrane-bound ATPase involved in replication and transcription and is notably decreased in patients with hepatocarcinoma [71]. Its deficiency is associated with abnormal cholesterol metabolism and mitochondrial DNA aggregation in central nervous system [72]. Knowing that mitochondrial ATAD3C is involved in cellular cholesterol homeostasis and that PCSK9 down-regulates LDLR expression and exogenous cholesterol uptake by LECs, its upregulation is expected.

Cholesterol synthesis is tightly related to cell proliferation [73, 74]. In general, proliferating cells show increased cholesterol synthesis and LDL receptor activity, which reflects the cellular lipid storage [75]. Contrariwise, cholesterol synthesis inhibitors can block cell proliferation [76-79]. Suppressing PCSK9 induces apoptosis and significantly alters the cell cycle of human keratinocytes, increasing the percentage of cells in S phase compared to control treatment [80]. To explore whether PCSK9 could exert its effect on lymphatic function by altering lymphatic endothelial cell cycle, human LEC were labeled with propidium iodide and the DNA content was measured to determine the proportion of cells in each phase of the cell cycle (Figure S5C) [29]. Our data revealed that exogenous PCSK9 did not modify the lymphatic endothelial cell cycle in vitro (Figure S5D). Our results thus suggest that decreasing LDLR expression at the protein level by itself might not be sufficient to alter LEC replication and integrity. Furthermore, it has been recently shown that PCSK9 is expressed in vascular smooth muscle cells and inhibits cell proliferation, thus affecting their function [81]. This data could explain the discrepancies observed our in vivo and in vitro model. Indeed, in vivo, PCSK9 might mediate its effect on lymphatic function by directly targeting lymphatic muscle cells in a LDLR-independent manner, rather than via lymphatic endothelial cells.
Silencing LEC-LDLR decreases VEGFR-3 expression at the protein but not at the mRNA level

In addition to investigating the effect of a total deletion in PCSK9 on lymphatic function, our in vivo model also pertained to downregulation of LDLR at the mRNA level. To explore the potential cellular mechanisms that could explain the differences we observed in the contraction capacity, we have treated human LEC with a siRNA targeting LDLR (siLDLR) or non-targeting siRNA (siCtl) in complete medium. LDLR mRNA levels were blunted following treatment with both sequences (Figures 4A-B). The expression of LDLR protein in whole cell lysate (Figure 4C) and in the cell membrane (Figure 4D) was also efficiently lessened. Knocking-down LDLR, however, did not affect the Pearson coefficient assessing the colocalization between LDLR and cholera toxin subunit B (average of 0.688 with siLDLR vs. 0.766 for control; Figure 4F). We observed a significant decrease in the proportion of LEC in the S phase when transfected with LDLR siRNA compared to the non-targeting siRNA treatment (Figure 4J). This observation provides a strong foundation for a novel role for LDLR in mediating the lymphatic endothelial cell cycle. Unlike other lymphatic markers involved in LEC proliferation and function such as LYVE-1...
membrane-bound VEGFR-3 was reduced upon LDLR siRNA treatment (Figure 4G). Yet, VEGFR-3 mRNA levels were unchanged (Figure 4E) compared to control siRNA. The fact that VEGFR-3 is modulated by the downregulation of LDLR mRNA could be a key element in our comprehension of the mechanism underlying the premature defect in lymphatic transport early in the atherosclerosis process. As VEGFR-3 diminished at the protein but not mRNA level, we suggest that a reduction in membrane cholesterol, a consequence of a reduction in LDLR, could potentially increase the turnover of membrane VEGFR-3. VEGFRs are promptly internalized into endocytotic vesicles to control their activity. VEGFR-2 has been shown to colocalize with lipid rafts to regulate its activation [82]. Furthermore, lipid rafts stabilize VEGFR-2 and its associated signal transduction activities required for angiogenesis [83]. If VEGFR-3 makes no exception, it would mean that changes in membrane lipids could also regulate the sensitivity of lymphatic endothelial cells to VEGFR-3 stimulation.

Silencing LEC-LDLR decreases total cellular cholesterol, cholesterol esters and key lipids involved in membrane integrity

Lipid rafts have a lifetime on the plasma membrane that ranges from seconds to minutes [84]. Albeit very labile, these segregations of lipids are typically enriched in free cholesterol and glycosphingolipids and regulate important cellular functions such as cellular polarity, vesicular traffic and signaling pathways [85]. Hence, we performed non-targeted lipidomic in siLDLR-treated human LEC to determine whether and how a downregulation in LDLR on LEC might change the cellular lipid composition and thus VEGFR-3 expression. First, we report that total cholesterol is decreased in cells treated with siLDLR compared to non-targeting siRNA (Figure 5A). In total, among the 2139 MS signals (or features) obtained following data processing, 80 features significantly discriminated siLDLR-treated cells from control cells (Figure 5B), and 18 unique lipid (sub)classes discriminating siLDLR- and siCtl- treated cells were further identified using MSMS analysis. Each dot represents a log2-transformed siLDLR/siCtl signal intensity ratio. (D) Extracellular vesicles produced by human LEC in vitro were quantified in supernatant by flow cytometry and (E) their total cholesterol content was measured following a 30 min incubation with a detergent ( Triton X-100) by spectrophotometry. EV, extracellular vesicles; CE, cholesterol esters; Cer, ceramides; GPs, glycerophospholipids; PC, phosphatidylcholine; PE(O-), phosphatidylethanolamine (plasmanylethanolamine); SLs, sphingolipids; TGs, triglycerides. “_” in TGs refers to acyl chains for which the position remains to be ascertained. n = 3-9. Statistics: ***p < 0.001, threshold P-value < 0.01.
among which we identified 18 unique lipids belonging to four main (sub) classes: cholesteryl esters, sphingolipids, glycerophospholipids and triglycerides (Figure 5C). Of all the lipids detected that have decreased following siLDLR treatment, phosphatidycholines and ceramides were identified. Phosphatidycholines are lipids which account for about 40% of phospholipids in cells [86]. Their suppression in blood endothelial cells prevents normal functioning of apoptosis signaling pathways [87]. Disturbance in the ratios of membrane lipids (phosphatidycholines to phosphatidylethanolamines) leads to the development of organ failure in mice caused by loss of membrane integrity of hepatocytes [88] and affects the normal processes of cell proliferation and viability [89]. Ceramides are important for the stability of the lipid bilayer [90] and they participate in the regulation of cell proliferation by inducing apoptosis under normal conditions [91, 92]. In addition, we observed lower levels of CE, a decrease concurring with total cholesterol decrease. Altogether, these published data suggest that lipid changes mediated upon silencing LDLR might affect LEC integrity and function in a similar way.

**Silencing LEC-LDLR alters VEGF-C mRNA, cholesterol biosynthesis, cell cycle processes and vesicle-mediated transport**

To explain these changes in membrane VEGFR-3 and lipids, we then sought to investigate whether siLDLR could increase the shedding of extracellular vesicles (EV) derived from the plasma membrane. Downregulating LDLR on LEC had no effect on the production of LEC-EV (Figure 5D). As we could not exclude that the EV production rate might remain unchanged but its composition different, we next measured the total cholesterol content of these EV. We show that cholesterol-EV is also unchanged compared to the control-treated group (Figure 5E), suggesting that plasma membrane cholesterol nor VEGFR-3 are not mobilized out of the cell through the production of extracellular vesicles. Transcriptomic analysis thus became insightful to better understand the potential signaling pathways involved in the alteration of lympathic integrity following LDLR siRNA transfection. First and foremost, the efficiency of siLDLR to downregulate LDLR in human LEC has been confirmed (Figure 6A). In total, siLDLR significantly upregulated 175 and downregulated 555 genes in human LEC (Figure 6B) with a fold change set at 1.5. Protein-protein interaction network (STRING database) based on RNA-transcriptomic analysis reveals that genes that are downregulated upon LDLR silencing are implicated in the cell cycle process, vesicle-mediated transport regulated exocytosis and cellular and metabolic processes (Figure 6D and Table 2). Among these genes, VEGF-C and VEGFR-2 (KDR) were downregulated as well as STAT3. STAT3 binds to VEGF-C promoter region and modulate lymphangiogenesis [93]. As VEGF-C binds to VEGFR-3 and lead to its regulation [94], the downregulation of VEGF-C by siLDLR could explain the downregulation of VEGF-3 protein. These data suggest that the lack of VEGF-C lead to a downregulation of VEGF-3 and VEGFR-2. Transcriptomic analysis also shows an upregulation of genes involved in cholesterol biosynthesis and cellular and metabolic processes (Figure 6C). Among the cholesterol regulating genes (MSMO1, TM7SF2, HMGCS1, DHCR7, ACAT2, IDI1 and FDFT1, Figure 6E), MSMO1 is one of most upregulated. Methylsterol monooxygenase 1 (MSMO1 previously SC4MOL) is localized in the endoplasmic reticulum (ER) membrane and is related to cholesterol biosynthesis I pathway by catalyzing the three-step monoxygenation required for the demethylation of 4,4-dimethyl and 4alpha-methylsterols, which can be subsequently metabolized to cholesterol [95]. Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) is also implicated in cholesterol biosynthesis. HMGCS1 in an enzyme which catalyses the production of mevalonate [96]. It was recently shown that HMGCS1 is a target to promote endothelial function in human umbilical vein endothelial cells (HUVECs) [97]. Based on our databank, FABP3 gene also appears upregulated following siLDLR treatment. Heart-type fatty-acid-binding protein 3 (FABP3) is a protein carrier transporting fatty acids and lipophilic substances from the cytoplasm to the nucleus mainly to maintain energy supply [98]. FABP3 was also found to regulate intramuscular fat content and improve insulin sensitivity [99, 100]. Being the response gene of peroxisome proliferator-activated receptor gamma (PPARy), FABP3 was demonstrated to have a direct impact on atherosclerosis, obesity and diabetes [101-103]. In human coronary artery endothelial cells (HCAECs), FABP3 regulates the transcriptional activities of lysophosphatidic acid (LPA) targeting PPARy [104]. FABP3 deficiency was also found to limit atherosclerosis development via inhibition of foam cell formation [101]. Furthermore, it was recently demonstrated that FABP3 mediate membrane lipid saturation, altering fluidity and inducing ER stress in skeletal muscle with aging [105]. The overexpression of FABP3 in muscles altered membrane lipid composition, in turn deteriorating muscle mass and force [105]. Given the prerequisite role of lymphatic muscle cells in lymphatic vessel contractility, this mechanism could explain the impairment in
lymphatic contraction we observe in vivo when LDLR is downregulated. As none of the β-oxidation, triglyceride synthesis or hydrolysis genes were significantly modulated upon LDLR silencing, the upregulation of ELOVL6 rather suggests that because of the lipid deprivation, siLDLR-treated LEC need more energy and will increase the rate of fatty acid synthesis to provide more energetic substrates for energy production through beta-oxidation. In addition, because of the observed decreased triglycerides content, another explanation may be a greater hydrolysis of triglycerides that will participate to the maintenance of adequate intracellular fatty acid supply for energy production [106].

Figure 6. siRNA targeting LDLR expression modulates genes related to cholesterol biosynthesis and cellular and metabolic processes. Human LEC were transfected for 48 h with 25 nM of non-targeting siRNA (siCtl) or siLDLR and transcriptomic analysis was performed. (A) The efficiency of the treatment to decrease LDLR is
represented. (B) Volcano plot of transcriptomic analysis performed in human LEC. Y axis = p value (-LOG10) of the gene expression, X axis = fold change siLDLR/siCtl (LOG2) of gene expression. Each point represents an individual gene. Significant upregulated and downregulated genes in siLDLR versus siCtl are depicted in red and blue, respectively. Using the R cluster Profiler package, function enrichment within significant genes (padj lower than 0.05 and fold change higher than 1.5), the following observed biological processes and enriched categories (using FDR adjustment to filter for 0.05 qValue cutoff) between siLDLR and siCtl was obtained. Biological processes implicated for (C) all the upregulated genes and (D) downregulated genes. (E) Protein-protein interaction network performed with the Search Tool for the Retrieval of Interacting Genes (STRING) database for all upregulated genes showed that cholesterol biosynthesis is the main biological process that is upregulated. n = 3. Statistics: *p < 0.05.

Table 2. Main biological process that are downregulated by siLDLR treatment compared to siCtl. n = 3

| #term ID      | Term description                  | Observed gene count | Background gene count |
|---------------|-----------------------------------|---------------------|-----------------------|
| GO:0007046    | Cell cycle                        | 129                 | 1313                  |
| GO:0022402    | Cell cycle process                | 96                  | 976                   |
| GO:0044770    | Cell cycle phase transition       | 35                  | 289                   |
| GO:0000075    | Cell cycle checkpoint             | 29                  | 198                   |
| GO:0009987    | Cellular process                  | 480                 | 15024                 |
| GO:0008152    | Metabolic process                 | 282                 | 8298                  |
| GO:0016192    | Vesicle-mediated transport        | 75                  | 1805                  |
| GO:0045055    | Regulated exocytosis              | 36                  | 697                   |
| GO:0006887    | Exocytosis                        | 39                  | 789                   |
| GO:0000082    | G1/S transition of mitotic cell cycle | 15               | 128                   |

Conclusion

Efficient lymphatic drainage is crucial for atherosclerosis regression [11, 12, 107]. Whereas hypercholesterolemia has previously been defined as the cornerstone between cardiovascular disease and lymphatic function [10, 13, 14], it is now known that lymphatic function is rather tightly regulated throughout the whole development of the atherosclerosis process. We herein sought to determine whether and how lymphatic endothelial-LDLR might modulate lymphatic function. We are reporting that PCSK9 is needed to reduce lymphatic contraction capacity in endothelial-specific LDLR knockdown mice. In vitro, exogenous PCSK9 only reduced LEC-LDLR at the protein level and did not affect lymphatic endothelial cell integrity. This puts forward that PCSK9 may act upon lymphatic muscle cells to mediate its effect on lymphatic contraction capacity in vivo. Rather, knocking down the expression of LDLR mRNA in human LEC decreased VEGFR-3 expression and modulated cellular lipids. Lipidomic and transcriptomic analysis revealed changes in lipid rafts and genes that are involved in cholesterol biosynthesis and cellular and metabolic processes upon LDLR mRNA downregulation in LEC. Our results suggest that treatments that specifically palliate the downregulation of Ldlr mRNA by LEC preserve the integrity of the lymphatic endothelium and sustain lymphatic function in chronic inflammatory conditions such as atherosclerosis.

Abbreviations

AAV1: Adeno-Associated Virus type 1; CVD: cardiovascular disease; EV: extracellular vesicles; FBS: fetal bovine serum; FITC: fluorescein isothiocyanate; HEK: human embryonic kidney; HuH7: hepatocytes; LDL: low-density lipoprotein; LDLR: low-density lipoprotein receptor; LEC: lymphatic endothelial cell; LN: lymph node; LVs: lymphatic vessels; LYVE-1: lymphatic vessel endothelial hyaluronic acid receptor-1; MFI: mean fluorescence intensity; PCSK9: proprotein convertase subtilisin kexin type 9; PDPN: podoplanin; ROI: region of interest; shRNA: short hairpin RNA; shSCR: scramble short hairpin RNA; siRNA: short-interfering RNA; VEGF-C 152S: vascular endothelial growth factor receptor-C; VEGFR-3: vascular endothelial growth factor receptor 3; Wt: C57BL/6 wild-type.

Supplementary Material

Supplementary figures. https://www.thno.org/v12p1440s1.pdf

Acknowledgements

The authors acknowledge Raphaëlle Lambert and Jennifer Huber at the Institute for Research in Immunology and Cancer (IRIC) genomics core facility for RNA sequencing as well as Patrick Gendron at the IRIC bio-informatics core facility for sequencing analysis. The authors would also like to Carl Fortin for his technical support with flow cytometry analysis and Caroline Daneault and Isabelle Robillard Frayne from the MHI Metabolomics core facility for performing the untargeted lipidomic analysis.

Financial support

This work was supported by funding from the Canadian Institutes for Health Research (FJ1-148627 and Canada Research Chair to CM, and MSc training grant to LV), the Heart and Stroke Foundation of Canada (CM) and the Fonds de Recherche du Québec - Santé (doctoral training grant, A.M.). MST was supported by NIH NHLBI HL 138907.

Author Contributions

LV*, AS* and NT* conducted experiments,
acquired and analyzed data and edited the manuscript; GJ and AM acquired and analyzed data; NT and SJ performed the in vivo injections and organs harvesting; NA, AD did AAV1 production and AA conducted the AAV1 constructions; LVilleneuve performed the confocal microscopy experiments; VF developed the LympHulse 3.0 software; MR performed the untargeted lipidomic analysis; MST provided scientific insights and edited the manuscript; GM provided the Pcsk9/- mice and edited the manuscript; CM designed research studies, acquired and analyzed data and wrote the manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Lemole GM. The role of lymphstasis in atherogenesis. Ann Thorac Surg. 1981; 31: 200-3.
2. Lemole GM, Sr. The role of Lymphstasis in Atherogenesis Revisited. Ann Thorac Surg. 2016; 101: 2092.
3. Curri LN, Detmar M. The lymphatic system in health and disease. Lymph Res Rev. 2008; 6: 109-22.
4. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009; 296: E1183-94.
5. Nakano T, Nakashima Y, Yonemitsu Y, Sumiyoshi S, Chen YX, Akishima Y, et al. Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol. 2005; 36: 330-40.
6. Ellis O, Ellisova M, Miller AJ. The absence of lymphatics in normal and atherosclerotic coronary arteries in man: a morphologic study. Lymphology. 2006; 39: 76-83.
7. Khlovak I, Dragmeva G, Cermakova P, Laidinen S, Kaskenpaa N, Hazes T, et al. Lymphatic vascularization is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest. 2011; 41: 487-97.
8. Drozdz K, Janczak D, Dzielj P, Podhorska M, Patrzalek D, Zioskiowski P, et al. Adventitial lymphatics of internal carotid artery and its dependence on the LDLR. Traffic. 2007; 8: 718-32.
9. Martel C, Randolph GJ. Atherosclerosis and transit of HDL through the lymphatic system. Lymphology. 2009; 42: 137-45.
10. Lim HY, Thiam CH, Yeo KP, Hii CS, McGrath KC, et al. In vivo visualization and quantification of collecting lymphatic vessel contractility using near-infrared imaging. Sci Rep. 2016; 6: 22950.
11. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Proto. 2006; 2: 1458-61.
12. Ponecet P, Robert S, Bailly N, Garnache-Ouattara F, Bouriche T, Devalet B, et al. Tips and tricks for flow cytometry-based analysis and counting of microparticles. Transfus Apher Sci. 2015; 53: 110-26.
13. Ponecet P, Robert S, Bouriche T, Bez J, Lacroix R, Dignat-George F. Standardized counting of circulating platelet microparticles using currently available flow cytometers and scatter-based triggering: Forward or side scatter? Cytometry A. 2016; 89: 145-58.
14. Beuthan J, Minet O, Hefmann J, Herrig M, Muller G. The spatial variation of the refractive index in biological cells. Phys Med Biol. 1996; 41: 369-82.
15. Morales-Kastresana A, Telford B, Musich TA, McKinnon K, Clayborne C, Braig Z, et al. Labeling Extracellular Vesicles for Nanoscale Flow Cytometry. Sci Rep. 2017; 7: 1878.
16. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30: 2114-20.
17. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast and memory-efficient RNA-seq aligner. Bioinformatics. 2013; 29: 15-21.
18. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12: 323.
19. Love MI, Huber W, Anders S. Moderated estimation of fold change and normalization for RNA-seq data. Annals of Applied Statistics. 2014; 8: 555-78.
20. Forest A, Royuau M, Bouchard B, Boucher G, Gingras O, Daneault C, et al. Reproducible and Comprehensive Untargeted Lipidomic Workflow Using LC-QTOF Validated for Human Plasma Analysis. J Proteome Res. 2018; 17: 3657-70.
21. Zawieja DC, Gasheva OY, Gashev AA. Contraction-initiated NO-dependent reactive oxygen metabolites inhibit spontaneous lymphatic contractions. Am J Physiol. 2015; 320: H1195-43.
74. Vitols S, Conner DA, Huang Y, Kucherlapati RS, Munn LL, et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A. 2011; 108: 18784-9.
75. Wang Y, Oliwier views on the function of the lymphatic vasculature in health and disease. Genes Dev. 2010; 24: 2115-26.
76. Morlosie F, Tatin F, Chappi A, Breville N, Vasse C, Metivier R, et al. Lymphatic Vasculature Requires Estrogen Receptor-alpha Signaling to Protect Against Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018; 38: 1346-57.
77. Li C, Briggs MR, Ashford TE, Kraemer FB, Liu J. Requirement of Sp1 and estrogen receptor alpha interaction in iBbeta-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression. Endocrinology. 2001; 142: 1846-52.
78. Lu DN, Cheng X, Zhu Y, Oslund JR, Berger SD, Dodd M, et al. Potentiation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors? Circulation. 2016; 134: 1695-6.
79. Chen HW, Kandutsch AA, Waymouth C. Inhibition of cell growth by sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. Circ Res. 2016; 118: 1294-312.
80. Ferrin N, Tibillo G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophage LDLR levels. Atherosclerosis. 2012; 220: 381-6.
81. Schulz R, Schulten KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2011; 106: 4.
82. Ding Z, Wang X, Liu S, Zhou S, Kore RA, Mu S, et al. NLRP3 inflammasome via IL-1beta regulates PCSK9 secretion. Thrombosis. 2020; 10: 7100-10.
83. Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, et al. Local estrogen induces PCSK9 in the aromatic nitric oxide synthase promoter activity. PLoS One. 2016; 11: e0155345.
84. Burke AC, Dron JS, Hegele RA, Huff MW. PCSK9: Regulation and Target for Drug Development for Dyslipidemia. Annu Rev Pharmacol Toxicol. 2017; 57: 381-368.
85. Bittner V. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors? Circulation. 2016; 134: 1695-6.
86. Liao S, Cheng G, Conner DA, Huang Y, Kucherlapati RS, Munn LL, et al. The ratio of phospholipid to cholesterol regulates the metabolic switch of human monocytes. Proc Natl Acad Sci U S A. 2011; 108: 18784-9.
87. Mathews ES, Mawdsley DJ, Walker M, Hines JH, Pozzoli M, Appel B. The relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 1993; 101: 117-25.
88. Isaksson BM, Brodin S, Skinski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A. 1991; 88: 3628-32.
89. Chakrabarti R, Englenman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte activation. J Biol Chem. 2003; 278: 22661-22.
90. Luan C, Chen X, Zhu Y, Oslund JR, Berger SD, Dodd M, et al. Potentiation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors? Circ Res. 2015; 110: 4.
91. Sorci C, Thomas MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis. Circ Res. 2016; 118: 679-91.
92. van der Veen JN, Kennedy JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylinositol and phosphatidylcholine metabolism in health and disease. Biochim Biophys Acta Membr. 2017; 1859: 1558-72.
93. Miao JY, Kaji K, Hayashi H, Araki S. Suppression of apoptosis by inhibition of phosphatidylinositol-specific phospholipase C in vascular endothelial cells. Endothelium. 1997; 5: 231-9.
94. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phospholipid to cholesterol regulates the metabolic switch of human monocytes. Proc Natl Acad Sci U S A. 2011; 108: 18784-9.
95. Huang HY, Yang HR, Huang SW, Ou G, Hsu YF, Hsu MJ. Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. PLoS One. 2016; 11: e0155345.
96. Zabroski IO, Nugent MA. Lipid Raft Association Stabilizes VEGF Receptor 2 in Endothelial Cells. Int J Mol Sci. 2021; 22.
97. Pralle A, Keller P, Florin EL, Simons K, Horber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol. 2000; 148: 997-1008.
98. Sonchi-Tommasi MG, Thomas MJ. Microdomains, Inflammation, and Atherosclerosis. Circ Res. 2016; 118: 679-91.
99. van der Veen JN, Kennedy JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylinositol and phosphatidylcholine metabolism in health and disease. Biochim Biophys Acta Membr. 2017; 1859: 1558-72.
100. Luan C, Chen X, Zhu Y, Oslund JR, Berger SD, Dodd M, et al. Potentiation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors? Circulation. 2015; 110: 4.
101. Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci. 1995; 20: 75-7.
102. Luan C, Chen X, Zhu Y, Oslund JR, Berger SD, Dodd M, et al. Potentiation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors? Circulation. 2015; 110: 4.
103. Mathews ES, Mawdsley DJ, Walker M, Hines JH, Pozzoli M, Appel B. The ratio of phospholipid to cholesterol regulates the metabolic switch of human monocytes. Proc Natl Acad Sci U S A. 2011; 108: 18784-9.
104. Me:H, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RL, et al. Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasis dermatitis, microcephaly, and developmental delay. J Clin Invest. 2011; 121: 976-84.
105. Shearer J, Fueger PT, Rottman JN, Bracy DP, Binas B, Wasserman DH. Heart-type fatty acid-binding protein reciprocally regulates glucose and fatty acid utilization during exercise. Am J Physiol Endocrinol Metab. 2005; 288: E321-31.
106. Zabroski IO, Nugent MA. Lipid Raft Association Stabilizes VEGF Receptor 2 in Endothelial Cells. Int J Mol Sci. 2021; 22.
107. Huang HY, Yang HR, Huang SW, Ou G, Hsu YF, Hsu MJ. Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. PLoS One. 2016; 11: e0155345.
108. Zabroski IO, Nugent MA. Lipid Raft Association Stabilizes VEGF Receptor 2 in Endothelial Cells. Int J Mol Sci. 2021; 22.
109. Pralle A, Keller P, Florin EL, Simons K, Horber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol. 2000; 148: 997-1008.
104. Tsukahara R, Haniu H, Matsuda Y, Tsukahara T. Heart-type fatty-acid-binding protein (FABP3) is a lysophosphatidic acid-binding protein in human coronary artery endothelial cells. FEBS Open Bio. 2014; 4: 947-51.

105. Lee S-M, Lee SH, Jung Y, Lee Y, Yoon JH, Choi JY, et al. FABP3-mediated membrane lipid saturation alters fluidity and induces ER stress in skeletal muscle with aging. Nature Communications. 2020; 11: 5661.

106. Wong BW, Wang X, Zecchin A, Thienpont B, Cornelissen I, Kalucka J, et al. The role of fatty acid β-oxidation in lymphangiogenesis. Nature. 2017; 542: 49-54.

107. Martel C, Li W, Fulp B, Platt AM, Gautier EL, Westerterp M, et al. Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest. 2013; 123: 1571-9.